Sugi Predict

Sugi Predict / Compounds / SCHEMBL1899309

SCHEMBL1899309

SCHEMBL1899309

O=C(O)c1ccc(-c2cc(C(=O)Nc3nnc(-c4ccco4)o3)c3ccccc3n2)cc1

nearest known ligand 0.87

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ STAT3 P40763 9/20 0.87
▸ LMNA P02545 7/20 0.60
▸ KDM4E B2RXH2 6/20 0.60
▸ TDP1 Q9NUW8 3/20 0.60
▸ SMN1; SMN2 Q16637 3/20 0.60
▸ MEN1 O00255 2/20 0.60
▸ HTT P42858 2/20 0.60
▸ KMT2A Q03164 2/20 0.60
▸ ALDH1A1 P00352 3/20 0.55
▸ GLA P06280 2/20 0.55
▸ HPGD P15428 2/20 0.55
▸ MAPK1 P28482 2/20 0.55
▸ CTDSP1 Q9GZU7 2/20 0.55
▸ HCRTR1 O43613 1/20 0.55
▸ MAPT P10636 1/20 0.55
▸ POLB P06746 2/20 0.54
▸ ESR1 P03372 1/20 0.54
▸ TP53 P04637 1/20 0.54
▸ GAA P10253 1/20 0.54
▸ HSD17B10 Q99714 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1899809 0.93 STAT3 (1.00) STAT3LMNAKDM4ETDP1SMN1; SMN2
SCHEMBL29382140 0.93 STAT3 (1.00) STAT3LMNAKDM4ETDP1SMN1; SMN2
SCHEMBL1901342 0.93 STAT3 (0.84) STAT3LMNAKDM4ETDP1SMN1; SMN2
SCHEMBL1900574 0.92 STAT3 (0.86) STAT3LMNAKDM4ETDP1SMN1; SMN2
SCHEMBL1899563 0.92 STAT3 (0.89) STAT3LMNAKDM4ETDP1SMN1; SMN2
SCHEMBL1898038 0.91 STAT3 (0.87) STAT3LMNAKDM4ETDP1SMN1; SMN2
SCHEMBL1898205 0.91 STAT3 (0.87) STAT3LMNAKDM4ETDP1SMN1; SMN2
SCHEMBL1898648 0.91 STAT3 (0.87) STAT3LMNAKDM4ETDP1SMN1; SMN2
SCHEMBL1900902 0.91 STAT3 (0.87) STAT3LMNAKDM4ETDP1SMN1; SMN2
SCHEMBL1899540 0.90 STAT3 (0.89) STAT3LMNAKDM4ETDP1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2325181-B1 STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT GENERAL INCORPORATED ASS PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) 2017-03-29 — — EP disclosed
US-8466290-B2 STAT3 inhibitor containing quinolinecarboxamide derivative as active ingredient PHARMA IP GENERAL INCORPORATED ASSOCIATION (JP) 2013-06-18 — — US disclosed
US-20110172429-A1 STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT PHARMA IP GENERAL INCORPORATED ASSOCIATION (JP) 2011-07-14 — — US disclosed
EP-2325181-A1 STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT Pharma Ip General Incorporated Association (JP) 2011-05-25 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172429-A1 STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT STAT3, STAT4, STAT5B STAT3 1/4885LMNA 4766/4885KDM4E 532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.